Cology, Antimitotic, Bio Response Modifiers

Front 1

antimitotic drug

Back 1

vinblastine

vincristine

vinorelbine

paclitaxol

docetaxel

topetecam

irinotecan

etoposide

teniposide

Front 2

inhibitors of growth factors

Back 2

imatinab

gefitinib

erlotinib

bortezomib

Front 3

antibodies to tumor cells antigens

Back 3

rituximab

alementuzumab

tratuzumab

cetuximab

bevacizumab

gemtuzumab ozagamicin

Front 4

antimitotic drugs:

interfere w/ --- process by altering --- formation or ----

--- phase specific

Back 4

mitotic

spindle

degradation

m-phase

Front 5

antimitotic:

inhibition of the -------- enzyme.

topoisomerase 1 breaks and reseals ----- stranded dna

topoisomerase 2 does the same on --- stranded dna

-- phase specific

Back 5

topoisomerase 1 or 2

single

double

Front 6

vinblastine alkaloid from vinca rosea --- plant

Back 6

periwinkle

Front 7

vincrisitne structural analog of ---

Back 7

vinblastine

Front 8

paclitaxel --- form bark of western yew tree

Back 8

alkaloid

Front 9

docetaxel --- from needles of european yew tree

Back 9

alkaloid

Front 10

etoposide semisynthetic ------ derived from mayapple or mandrake plant

Back 10

podophyllotoxins

Front 11

teniposide structural analog of ---

Back 11

etoposide

Front 12

topotecan synthetic --- from camptotheca acuminata

Back 12

camptothecin

Front 13

mitotic agent interfere w/ ----

prevent --- of dna strands in cell

arrest --- ----

Back 13

microtubules

separation

cell division

Front 14

mitotic agent

stopping cell division leads to -- ---

Back 14

cell death

Front 15

vinca alkaloid route

Back 15

iv

Front 16

t/f

vinca alkaloid enters cns

Back 16

f

does not

Front 17

vinca alkaloid goes thru extensive ----

Back 17

metabolism

Front 18

vinca alkaloid


--- excretion

Back 18

biliary

Front 19

ex of vinca alkaloid

Back 19

vincristine

vinblastine

Front 20

vincristine tx:

Back 20

lymphomas

acute lympocytic leukemia

hodgkin's some solid tumors

Front 21

vincristine part of the --- tx

Back 21

MOPP

vincristine = oncovine

Front 22

vinblastine used to tx

Back 22

hodgkin's

bladder

breast

ovarian

testicular

Front 23

vinblastine part of the --- tx

Back 23

ABVD

vinblastine = velbane

Front 24

which is used more for solid tumors:

vincristine or vinblastine

Back 24

vinblastine

Front 25

tox of vinca alkaloids

rapid --- effects and cell ----

leads to hyper------ due to oxidation of the purine to --- acid

use:

Back 25

cytotoxic

cell destruction

hyperuricemia

uric acid

use allopurinol to prevent buildup

Front 26

vinca alkaloids:

strong ------

Back 26

vesicants

Front 27

tx of vesicant action of vinca alkaloids

Back 27

heat

hyaluronidase

(to disperse drug)

Front 28

vincristine tox

dose limiting --- toxicity

peripheral ----- of hands and feet

may affect both --- and ---- nerves

Back 28

neurotoxicity

periphral neuropahty

sensory and motor nerves might be affected

Front 29

vincristine tox

suppresion of --- -----

-- nerve damage may cause -- pain face -----

Back 29

suppresion of deep tendon reflexes

cranial nerve damage

jaw pain

face palsies

Front 30

vincristine tox

--- neuropathies

Back 30

autonomic

Front 31

vincristine tox

may cause --- suppression

Back 31

myelosuppression

Front 32

main vincristine tox

Back 32

hand and glove

Front 33

vinblastine tox

dose limiting ------

less --- toxic

-- --- ---

Back 33

mylesuppression

neurotoxic

n/v/d

Front 34

vinorelbine --------- ---- ca

Back 34

non small cell lung ca

Front 35

vinorelbine is a semisynthetic analog of ---

Back 35

vinblastine

Front 36

vinorelbine tox

---suppression

-- --- --

-- tox

Back 36

myelosuppresion

n/v/d

neurotoxicity

Front 37

paclitaxel/docetaxel

1971: spindle poison

increasae tubulin ------

decrease ------

Back 37

polymerization

disassembly

Front 38

paclitaxel/docetaxel

cell division stopped in ----

Back 38

m phase

Front 39

paclitaxel/docetaxel txs

Back 39

metastatic ovarian breast, lung, esophageal, head/neck tumors

Front 40

paclitaxel tox

-- suppresion

---- rxns

-- ---- sensory neuropathy

---gia

Back 40

myelosuppresion

hypersensitivity rxn

stocking-glove sensory neuropathy

myalgia

Front 41

docetaxol tox

---penia

less sever -- pathy

less -- rxn

----

Back 41

neutropenia

less severe neuropathy

less hypersensitivity rxns

edema

Front 42

etoposide/teniposide

cell cycle spicific for:

Back 42

S-G2

Front 43

etoposide/teniposide

------ breaks and reseals dna breaks during uncoiling

Back 43

topoisomerase 2

Front 44

etoposide/teniposide

agenst blocks enzymes leading to --- ----

Back 44

strand breaks

Front 45

route of etoposide

Back 45

oral

IV

Front 46

etoposide 40% excreted unchanged via

Back 46

urine

Front 47

tenipside is extensively ---

Back 47

metabolized

Front 48

etoposide txs

Back 48

testicular

lung

nonhodgkin's lymphoma

Front 49

etoposide:

often given in combo w/

Back 49

cisplatin

Front 50

teniposide route

Back 50

IV

Front 51

tenoposide txs

Back 51

acute lymphocytic leukemia

neuoblastoma

Front 52

teniposide:

check --- fx

Back 52

liver

Front 53

etoposide/teniposide tox

---cia

----/----

dose limiting ------

Back 53

alopecia

n/v


dose limiting myelosuppression

Front 54

etoposide leads to unusual -- ---- -- due to alteration in chromosome ----

Back 54

nonlymphocytic leukemia

chromosome 11

usu 1-3 yrs after tx after childhood acute lymphoblasitic leukemia

Front 55

chormosome 11: ---- ---- leukemia gene

Back 55

MLL: mixed lineage leukemia gene

Front 56

unusual nonlymphocytic leukemia occurs after what disease

Back 56

acute lymphoblastic leukemia

Front 57

irinotecan/topotecan

synthetic ----

Back 57

camptothecins

Front 58

irinotecan/topotecan

greater activity than --- ---

Back 58

natural alkaloid

Front 59

irinotecan/topotecan

inhibits ----- causing -- strand breaks in dna

Back 59

topoisomerase 1

single

Front 60

irinotecan

metabolized and excreted in ---

Back 60

bile

Front 61

topotecan

-- excretion

Back 61

renal

Front 62

irinotecan used to tx

Back 62

colorectal

breast

cervical

gastric

lung

Front 63

topotecan used to tx

Back 63

lung

ovarian

cml

Front 64

irinotecan/topotecan tox

dose-limiting ------

Back 64

myelosuppression

Front 65

which causes more diarrhea

irinotecan or topotecan

Back 65

irinotecan>>>topotecan

Front 66

irinotecan/topotecan tox

--- ----

--- cia

Back 66

n/v

alopecia

Front 67

irinotecan

has decreases --- activity

Back 67

cholinesterase

so increased ACTH acitvity

increased muscarinic type effects

Front 68

biological response modifers. . .protein kinases:

genomoe codes for ----- protein kinases and 130 ---- -----

Back 68

550

protein phosphatases

Front 69

protein kinases:

critical part of the --- -----pathways

Back 69

signal transduction

Front 70

two types of protein kinases

Back 70

receptor tyrosine kinases (humans-90)

enzymatic tyrosine kinases (humans - 32)

Front 71

rtk stimulates ----

leads to proliferatin of cells

Back 71

RAS

Front 72

myeloid tyrosine kinase inhibitor:

Back 72

Imatinib

Front 73

-nib

Back 73

tyrosine inhibitor

Front 74

imatinib used to tx:

Back 74

cml

cmml

Front 75

imatinib decrease --- --- responsible for cell proliferation

Back 75

myeloid TK's

Front 76

se of imatinab

Back 76

n/v

edema

Front 77

epidermal growth factor tyrosine kinase inhibitor:

Back 77

gefitinib

Front 78

gefitinib txs

Back 78

nonsmall cell lung

Front 79

gefitinib se

Back 79

diarrhea

rash

nausea

vomiting

dry skin

Front 80

biological response modifiers blocks recpetors so growth factors can't bind ot stimulate -- --

Back 80

tyrosine kinase

Front 81

HER1/EGFR tyrosine kinase inhbitor

Back 81

erlotib

Front 82

erlotnib used to tx

Back 82

mestatic non small cell lung ca

pancreatic

head

neck

Front 83

se of erlotnib

Back 83

diarrhea

rash

elevated liver enzymes

Front 84

ErbB1, ErbB2 TK inhibtors

Back 84

lapatinib

Front 85

lapatinib route

Back 85

oral

Front 86

lapatinib approved for

Back 86

metastatic breast ca no longer sensitive to transtuzumab

Front 87

lapatinib used in combo w/

Back 87

capecitabine

increased time for tumor growth from ~ 4.4 to 8 mo

Front 88

t/f

lapatinib used for both her1 and 2

Back 88

t

Front 89

t/f

lapatinib enters cns

Back 89

t

so effective for cns metastasis

Front 90

lapatinib tox

Back 90

rash

nausea

fatigue

anorexia

Front 91

t/f

lapatinib allows gf to bind but not tf

Back 91

t

Front 92

proteosome inhibitor

Back 92

bortezomib

Front 93

bortezomib increase -- and decrease ----- -----

Back 93

increase IkB (inhbits NFKB. .. survival factor)

IkB prevents survival of Ca cells

decrease NFkB and NFkB cell survior promoter genes

Front 94

bortezomib used for

Back 94

multiple myeloma

trials in solid tumor

Front 95

bortezomib tox

------

------penia

----thy

---- pain

Back 95

fatigue

thrombocytopenia

neuropathy

limb pain

Front 96

rituximab

chimeric human-murine antibody to --- antigen on -- lymphocytes

Back 96

CD20

B

Front 97

90% of ---- cells expressed on CD20 antigen

Back 97

non-hodgkin's lymphoma

Front 98

CD20 regulates steps in -- ---- activation

Back 98

cell-cycle

Front 99

blocking CD20:

complement mediated:

Back 99

lysis

apoptosis

antibody mediated cytotoxicity

Front 100

rituximab given as 4 --- infusions

Back 100

weekly

Front 101

rituximab tox:

infusion related --- -- syndrome

-- ---

--ria

--spasm

mild -----

Back 101

flu like syndrome

n/v

uticaria

bronchospasm

mild myelosuppression

Front 102

alemtuzumab binds CD--- antigen on -- and --- lymphomas

Back 102

CD52

T

B

Front 103

alemtuzumab induces cellular ----

Back 103

cytotoxicity

Front 104

indications for alemtuzumab

Back 104

lympomas

CLL

Front 105

alemtuzumab tox

-- rxn

decreased ---

--- infections

Back 105

infusion

decreased T cells

opportunistic infections

Front 106

trastuzumab recombinant human --- antibody to human --- --- ---- 2

Back 106

monoclonal

epidermal growth factor 2 (her 2/neu, erbB2)

Front 107

trastuzumab antibody prevents binding of --- ----

can also down regulate --- ---- ----

Back 107

growth factor

growth facotr receptor

Front 108

trastuzumab used for

Back 108

metastatic breast tumors over expressing HER2 (erbB2)oncogene

Front 109

trastuzumab used w/

Back 109

doxorubicin

taxol

Front 110

trastuzumab

--- overexpression in 25-30% primary -- ---

Back 110

protein

breast ca

Front 111

trastuzumab tox

--- --- (weekly infusion)

what do u tx w/

Back 111

fever

chills

tx: apap, diphnehydamine, meperidine

Front 112

trastuzumab tox

----- ------

--ache

---ness

--nia

---

--myopathy

Back 112

n/v

ha

dizziness

dyspnea

cough cardiomyopathy

Front 113

cetuximab

antibody to --- --- ---

Back 113

epidermal growth factor

Front 114

cetuximab tx:

Back 114

metastatic colorectal ca

head

neck

Front 115

cetuximab tox

-- rxn

skin rash

Back 115

infusion

skin rash

Front 116

bevacizumab

antibody to ----- --- growth factor

Back 116

vascular-endothelial

(VEGF)

Front 117

bevacizumab prevents

Back 117

agiogeneis

block bl supply to tumor. . .slows growth

Front 118

bevacizumab indications:

Back 118

metastatic colorectal

breast

lung

renal pancreatic

Front 119

bevacizumab tox:

severe ----

---uria

---

Back 119

severe htn

proteinuria

CHF

Front 120

gentuzumab ozogamicin antibody to --- antigen linked to ozagamicin

Back 120

cd33

Front 121

gentuzumab ozogamicin

indication

Back 121

cd33 positive acute myelogenous leukemia in first relapse

Front 122

gentuzumab ozogamicin tox

--- rxn

-- and -- suppression

Back 122

infusion rxn

hepatic and bone marrow suppression

Front 123

gentuzumab ozogamicin

is a --- drug

Back 123

combo of angibody w/ antitumor abx

target tumor them kills

Front 124

t/f

gentuzumab ozogamicin is 1st line

Back 124

f

Front 125

D,L-Asparaginase

---- required for protein synthesis

Back 125

asparagine

Front 126

D,L-Asparaginase

--- cells take up from plasma anc can synthesize

Back 126

norm

Front 127

--- tumors have low levels of asparagine synthetase

so must take up ----

Back 127

lymphoid

asparagine

Front 128

---- depletes asparagine for protein synthesis in ca cells

Back 128

asparaginase

Front 129

D,L-Asparaginase

used in

Back 129

childhood acute lympocytic leukemia

Front 130

D,L-Asparaginase used in combo w/

Back 130

methotrexate

doxorubicin

vincristine

Front 131

what's given first methotrexate or D,L-Asparaginase

Back 131

methotrexate

D,L-Asparaginase stops protein synthesis and prevents methotrexate from working

Front 132

D,L-Asparaginase causes

--- rxn

Back 132

allergic

Front 133

D,L-Asparaginase tox

--- hemorrhage

----tis

Back 133

intracranial hemorrhage

pancreatitis

Front 134

D,L-Asparaginase

decrease --- factors

Back 134

clotting

Front 135

D,L-Asparaginase

---- toxicity

Back 135

ammonia